CN1498624A - Puerarin gelation for eye use and prepn. method - Google Patents
Puerarin gelation for eye use and prepn. method Download PDFInfo
- Publication number
- CN1498624A CN1498624A CNA021451397A CN02145139A CN1498624A CN 1498624 A CN1498624 A CN 1498624A CN A021451397 A CNA021451397 A CN A021451397A CN 02145139 A CN02145139 A CN 02145139A CN 1498624 A CN1498624 A CN 1498624A
- Authority
- CN
- China
- Prior art keywords
- gel
- puerarin
- injection
- water
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 80
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title description 8
- 238000001879 gelation Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000008215 water for injection Substances 0.000 claims abstract description 26
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 25
- 229960001631 carbomer Drugs 0.000 claims abstract description 25
- 229910021538 borax Inorganic materials 0.000 claims abstract description 19
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004327 boric acid Substances 0.000 claims abstract description 19
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 19
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 19
- 229940100655 ophthalmic gel Drugs 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 abstract description 8
- 208000010412 Glaucoma Diseases 0.000 abstract description 7
- 210000003462 vein Anatomy 0.000 abstract description 6
- 210000001367 artery Anatomy 0.000 abstract description 5
- 210000001525 retina Anatomy 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 239000003889 eye drop Substances 0.000 description 31
- 239000003814 drug Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000004410 intraocular pressure Effects 0.000 description 16
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 230000004089 microcirculation Effects 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 206010023683 lagophthalmos Diseases 0.000 description 6
- -1 nonirritant Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 description 2
- 206010041956 Stasis syndrome Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 208000005634 blind loop syndrome Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- 208000007950 Ocular Hypotension Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 241000539609 Pueraria pseudohirsuta Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Group | Dosage % | Number of animals only | Score value flows | ||
10min 15min 5min after the preceding administration of administration before the modeling | ????20min | ????30min | |||
Model control group | - | 10 | ??0.30±0.48??2.50±0.53??2.40±0.52????2.44±0.53????2.30±0.48 | ??2.20±0.63 | ??2.10±0.57 |
Eye drop gel for eye use size | ????1 ????1 ???0.5 | ??10 ??10 ??10 | 0.30±0.48??2.70±0.48??2.20±0.63??1.22±0.83 **???0.90± ?????????????????????????????????????????????????????????????????????????????????????????????????????????0.88 **0.20±0.42??2.40±0.52??1.90±0.57??1.20±0.79 **???0.80± ?????????????????????????????????????????????????????????????????????????????????????????????????????????0.63 **0.40±0.52??2.50±0.53??2.30±0.67??1.10±0.74 **???1.10±0.74 | ?1.10±0.74 **?0.60±0.52 **?1.50±0.53 * | ??1.30±0.95 *??0.60±0.69 **??2.00±0.67 |
Group | Dosage % | Number of animals only | Score value flows | ||
10min 15min 5min after the preceding administration of administration before the modeling | ????20min | ????30min | |||
Model control group eye drop gel for eye use size | ????- ????1 ????1 ???0.5 | ??10 ??10 ??10 ??10 | ??6.5±1.08????3.5±1.08????3.3±1.25????3.2±1.03??????3.4±0.84 ??6.7±1.16????3.5±0.97????4.0±1.15????4.4±0.97 **???4.9±0.99 **??6.8±1.32????3.2±1.03????4.0±0.82????5.0±1.15 **???5.4±1.17 **??6.7±1.16????3.6±1.07????3.5±0.71????3.9±0.99??????4.3±0.95 * | ????3.4±0.97 ????5.1±1.1 **????5.5± ????????1.72 **????4.6± ?????????0.97 ** | ????3.5±0.71 ????5.2±1.03 *????6.4±1.35 **Δ????????4.6±1.07 * |
Group | Dosage % | Number of animals only | Intraocular pressure value (Kpa) | ||
After the normal intraocular tension modeling after the administration 0.5 day 1 day 3 days | 5 days | 7 days | |||
Blank model control group eye drop gel for eye use size | ????- ????- ????1 ????1 ???0.5 | ??12 ??12 ??12 ??12 ??12 | ??2.49±0.08????2.50±0.09??????2.51±0.07??????2.50±0.07??????2.49±0.07 ??2.52±0.05????6.84±0.23 Δ??????6.78±0.23 Δ??????6.24±0.26 Δ??????5.66±0.35 Δ????2.49±0.01????6.81±0.34??????6.59±0.39??????5.33±0.47 **???4.11±0.49 **??2.50±0.02????6.86±0.28??????6.46±0.36 *????5.30±0.32 **???3.22±0.25 **??2.50±0.01????6.84±0.20??????6.66±0.31??????6.20±0.29??????5.12±0.36 ** | ??2.49±0.06 ??4.85±0.45 Δ????2.9±0.24 **??2.66±0.19 **??3.56±0.43 ** | ??2.50±0.06 ??3.28±0.45 ??2.55±0.13 **??2.50±0.10 **??2.82±0.24 ** |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02145139 CN1268344C (en) | 2002-11-05 | 2002-11-05 | Puerarin gelation for eye use and prepn. method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02145139 CN1268344C (en) | 2002-11-05 | 2002-11-05 | Puerarin gelation for eye use and prepn. method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1498624A true CN1498624A (en) | 2004-05-26 |
CN1268344C CN1268344C (en) | 2006-08-09 |
Family
ID=34232278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02145139 Expired - Lifetime CN1268344C (en) | 2002-11-05 | 2002-11-05 | Puerarin gelation for eye use and prepn. method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1268344C (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1316975C (en) * | 2005-09-16 | 2007-05-23 | 四川三精升和制药有限公司 | Puerarin prepn for eye and its prepn process |
CN101926788B (en) * | 2009-06-18 | 2012-12-19 | 刘力 | Cardiovascular/cerebral and ophthalmological medicines, and preparation and use thereof |
CN104688672A (en) * | 2014-12-29 | 2015-06-10 | 浙江莎普爱思药业股份有限公司 | Application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases |
CN112972683A (en) * | 2019-12-13 | 2021-06-18 | 刘力 | Locally administered medicinal composition of gellinzomib and the like |
CN113786380A (en) * | 2021-09-18 | 2021-12-14 | 华北制药股份有限公司 | Pilocarpine nitrate ophthalmic gel and preparation method thereof |
CN115998943A (en) * | 2022-12-20 | 2023-04-25 | 北京中医药大学 | Hydrogel for promoting skin wound healing and application thereof |
CN116474154A (en) * | 2022-12-20 | 2023-07-25 | 北京中医药大学 | Hydrogel dressing band-aid for diabetes wound and application thereof |
CN115998943B (en) * | 2022-12-20 | 2024-05-24 | 北京中医药大学 | Hydrogel for promoting skin wound healing and application thereof |
-
2002
- 2002-11-05 CN CN 02145139 patent/CN1268344C/en not_active Expired - Lifetime
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1316975C (en) * | 2005-09-16 | 2007-05-23 | 四川三精升和制药有限公司 | Puerarin prepn for eye and its prepn process |
CN101926788B (en) * | 2009-06-18 | 2012-12-19 | 刘力 | Cardiovascular/cerebral and ophthalmological medicines, and preparation and use thereof |
CN104688672A (en) * | 2014-12-29 | 2015-06-10 | 浙江莎普爱思药业股份有限公司 | Application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases |
CN104688672B (en) * | 2014-12-29 | 2018-01-30 | 浙江莎普爱思药业股份有限公司 | Puerarin gel eyedrop is preparing the application in treating retinopathy medicine |
CN112972683A (en) * | 2019-12-13 | 2021-06-18 | 刘力 | Locally administered medicinal composition of gellinzomib and the like |
CN113786380A (en) * | 2021-09-18 | 2021-12-14 | 华北制药股份有限公司 | Pilocarpine nitrate ophthalmic gel and preparation method thereof |
CN115998943A (en) * | 2022-12-20 | 2023-04-25 | 北京中医药大学 | Hydrogel for promoting skin wound healing and application thereof |
CN116474154A (en) * | 2022-12-20 | 2023-07-25 | 北京中医药大学 | Hydrogel dressing band-aid for diabetes wound and application thereof |
CN116474154B (en) * | 2022-12-20 | 2024-05-14 | 北京中医药大学 | Hydrogel dressing band-aid for diabetes wound and application thereof |
CN115998943B (en) * | 2022-12-20 | 2024-05-24 | 北京中医药大学 | Hydrogel for promoting skin wound healing and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1268344C (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100307685B1 (en) | Controlled Release of Miotic and Mydriatic Drugs in the Anterior Chamber | |
CN1185009C (en) | Eye preparation | |
DE69828993T2 (en) | CONTROLLED DELIVERY OF PHARMACEUTICALS IN THE FRONT EYE CHAMBER | |
US20130040960A1 (en) | Ophthalmic gel of gatifloxacin and preparation method thereof | |
CN101203236A (en) | Prophylactic or therapeutic agent for conrneal/conjunctival disease | |
CN1268344C (en) | Puerarin gelation for eye use and prepn. method | |
CN101401791A (en) | Timolol liposome and preparation method thereof | |
CN101269220B (en) | Rapamycin eye-in implantation type medicine release system with bletilla striata glue as carrier | |
CN1302812C (en) | Transmission system of medicine containing trehalose and hyaluronic acid for eye part and its preparation method | |
CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
CN104324038B (en) | A kind of purposes of diosgenin -3- bit derivants | |
CN102166205A (en) | New medical application of paeonol and derivatives thereof | |
CN101543509B (en) | Ophthalmic gel containing chondroitin sulfate and method for preparing same | |
CN101579305A (en) | Ready-to-use puerarin ophthalmic gel | |
CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
CN103735518B (en) | The preparation method of timolol maleate sustained-release micro-spheres | |
KR100287991B1 (en) | Ophthalmic Argatroban Formulations | |
CN105902486B (en) | A kind of efficient targeting to gasserian ganglion hydroxytyrosol eye drops and preparation method thereof | |
CN110859835B (en) | Application of butylphthalide in preparation of medicine for treating corneal injury | |
RU2288702C1 (en) | Irrigation solution for ophthalmology | |
CN108524448B (en) | A kind of euphadienol anti-cataract eye-drops preparations and its preparation method and application | |
CN112263545A (en) | Ophthalmic composition and preparation method and application thereof | |
CN101396339B (en) | Novel degradable lacrimal passage plug and preparation method thereof | |
RU2284181C2 (en) | Pharmaceutical composition for prophylaxis of ophthalmological infections | |
JP3530542B2 (en) | Argatroban formulation for ophthalmology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG UNIVERSITY, ZHEJIANG PHARMACEUTICAL LIFE Free format text: FORMER OWNER: PHARMACEUTICAL CO., LTD. OF ZHEJIANG UNIV. Effective date: 20080801 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080801 Address after: Hangzhou City, Zhejiang province Jianggan District nine loop nine town No. 48 Building 1 Patentee after: Zhejiang University Shengming Pharmaceutical Co.,Ltd. Address before: No. 268, triumph Road, Zhejiang, Hangzhou Patentee before: PHARMACEUTICAL Co.,Ltd. ZHEJIANG |
|
C56 | Change in the name or address of the patentee |
Owner name: ZHEJIANG QUANJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: ZHEJIANG UNIVERSITY, ZHEJIANG PHARMACEUTICAL LIFE CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Hangzhou City, Zhejiang province Jianggan District nine loop nine town No. 48 Building 1 Patentee after: Zhejiang all gold Pharmaceutical Co.,Ltd. Address before: Hangzhou City, Zhejiang province Jianggan District nine loop nine town No. 48 Building 1 Patentee before: Zhejiang University Shengming Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee after: ZHEJIANG QUANJIN PHARMACEUTICAL Co.,Ltd. Address before: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee before: Zhejiang all gold Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: BEST WORLD (ZHEJIANG) PHARMACEUTICAL INDUSTRY CO., Free format text: FORMER NAME: ZHEJIANG QUANJIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee after: Zhejiang all gold Pharmaceutical Co.,Ltd. Address before: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee before: ZHEJIANG QUANJIN PHARMACEUTICAL Co.,Ltd. Address after: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee after: BEST WORLD (ZHEJIANG) PHARMACEUTICAL CO.,LTD. Address before: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee before: Zhejiang all gold Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: Hangzhou City, Zhejiang province 310019 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee after: All American world (China) Pharmaceutical Co.,Ltd. Address before: Hangzhou City, Zhejiang province 310023 nine Ring Road in Jianggan District nine town No. 48 Building 1 Patentee before: BEST WORLD (ZHEJIANG) PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term |
Granted publication date: 20060809 |
|
CX01 | Expiry of patent term |